Does the media prefer ARQT or GYRE?

In the previous week, Arcutis Biotherapeutics and Arcutis Biotherapeutics both had 2 articles in the media. Arcutis Biotherapeutics' average media sentiment score of 0.42 beat Gyre Therapeutics' score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor GYRE or MBX?

In the previous week, MBX Biosciences had 3 more articles in the media than Gyre Therapeutics. MarketBeat recorded 5 mentions for MBX Biosciences and 2 mentions for Gyre Therapeutics. MBX Biosciences' average media sentiment score of 0.24 beat Gyre Therapeutics' score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate RGC or GYRE?

Gyre Therapeutics has a consensus target price of $16.00, suggesting a potential upside of 125.04%. Given Gyre Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gyre Therapeutics is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gyre Therapeutics 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has better earnings and valuation, RGC or GYRE?

Gyre Therapeutics has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Gyre Therapeutics $116.59M 6.80 $5.03M -$0.21 N/A

Does the media refer more to RGC or GYRE?

In the previous week, Gyre Therapeutics had 1 more articles in the media than Regencell Bioscience. MarketBeat recorded 2 mentions for Gyre Therapeutics and 1 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 0.00 equaled Gyre Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer MOR or GYRE?

Gyre Therapeutics has a consensus target price of $16.00, suggesting a potential upside of 125.04%. Given Gyre Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Gyre Therapeutics is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Gyre Therapeutics 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is MOR or GYRE more profitable?

Gyre Therapeutics has a net margin of -15.47% compared to MorphoSys' net margin of -226.79%. Gyre Therapeutics' return on equity of -6.57% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Gyre Therapeutics -15.47% -6.57% -5.35%

Gyre Therapeutics (GYRE) Competitors

$7.11 +0.11 (+1.57%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$7.12 +0.01 (+0.14%)

As of 10/2/2026 07:30 PM Eastern

Compare

GYRE vs. ARQT, MBX, RGC, MOR, and ATAI

Should you buy Gyre Therapeutics stock or one of its competitors? Gyre Therapeutics's main competitors and comparable companies include Arcutis Biotherapeutics (ARQT), MBX Biosciences (MBX), Regencell Bioscience (RGC), MorphoSys (MOR), and Atai Beckley (ATAI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Gyre Therapeutics compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Gyre Therapeutics (NASDAQ:GYRE) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Gyre Therapeutics has lower revenue, but higher earnings than Arcutis Biotherapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.41	-$16.14M	$0.21	119.81
Gyre Therapeutics	$116.59M	6.80	$5.03M	-$0.21	N/A

24.0% of Gyre Therapeutics shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Arcutis Biotherapeutics has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Gyre Therapeutics' net margin of -15.47%. Arcutis Biotherapeutics' return on equity of 15.05% beat Gyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Gyre Therapeutics	-15.47%	-6.57%	-5.35%

Arcutis Biotherapeutics presently has a consensus price target of $35.57, suggesting a potential upside of 41.38%. Gyre Therapeutics has a consensus price target of $16.00, suggesting a potential upside of 125.04%. Given Gyre Therapeutics' higher probable upside, analysts plainly believe Gyre Therapeutics is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Arcutis Biotherapeutics and Arcutis Biotherapeutics both had 2 articles in the media. Arcutis Biotherapeutics' average media sentiment score of 0.42 beat Gyre Therapeutics' score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Arcutis Biotherapeutics beats Gyre Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Gyre Therapeutics compare to MBX Biosciences?

Gyre Therapeutics (NASDAQ:GYRE) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

Gyre Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

MBX Biosciences has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -15.47%. Gyre Therapeutics' return on equity of -6.57% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-15.47%	-6.57%	-5.35%
MBX Biosciences	N/A	-26.02%	-24.94%

In the previous week, MBX Biosciences had 3 more articles in the media than Gyre Therapeutics. MarketBeat recorded 5 mentions for MBX Biosciences and 2 mentions for Gyre Therapeutics. MBX Biosciences' average media sentiment score of 0.24 beat Gyre Therapeutics' score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gyre Therapeutics has higher revenue and earnings than MBX Biosciences. Gyre Therapeutics is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	6.80	$5.03M	-$0.21	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

24.0% of Gyre Therapeutics shares are owned by institutional investors. 9.5% of Gyre Therapeutics shares are owned by insiders. Comparatively, 31.1% of MBX Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Gyre Therapeutics presently has a consensus price target of $16.00, indicating a potential upside of 125.04%. MBX Biosciences has a consensus price target of $83.89, indicating a potential upside of 43.38%. Given Gyre Therapeutics' higher possible upside, analysts clearly believe Gyre Therapeutics is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

Summary

Gyre Therapeutics and MBX Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Gyre Therapeutics compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Gyre Therapeutics (NASDAQ:GYRE) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Gyre Therapeutics has a consensus target price of $16.00, suggesting a potential upside of 125.04%. Given Gyre Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gyre Therapeutics is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Regencell Bioscience has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market.

Gyre Therapeutics has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Gyre Therapeutics	$116.59M	6.80	$5.03M	-$0.21	N/A

Regencell Bioscience has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -15.47%. Regencell Bioscience's return on equity of 0.00% beat Gyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Gyre Therapeutics	-15.47%	-6.57%	-5.35%

In the previous week, Gyre Therapeutics had 1 more articles in the media than Regencell Bioscience. MarketBeat recorded 2 mentions for Gyre Therapeutics and 1 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 0.00 equaled Gyre Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Gyre Therapeutics beats Regencell Bioscience on 9 of the 12 factors compared between the two stocks.

How does Gyre Therapeutics compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Gyre Therapeutics (NASDAQ:GYRE) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

18.4% of MorphoSys shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Gyre Therapeutics has a consensus target price of $16.00, suggesting a potential upside of 125.04%. Given Gyre Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Gyre Therapeutics is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Gyre Therapeutics has lower revenue, but higher earnings than MorphoSys. Gyre Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Gyre Therapeutics	$116.59M	6.80	$5.03M	-$0.21	N/A

MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market.

Gyre Therapeutics has a net margin of -15.47% compared to MorphoSys' net margin of -226.79%. Gyre Therapeutics' return on equity of -6.57% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Gyre Therapeutics	-15.47%	-6.57%	-5.35%

In the previous week, Gyre Therapeutics had 2 more articles in the media than MorphoSys. MarketBeat recorded 2 mentions for Gyre Therapeutics and 0 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.00 equaled Gyre Therapeutics'average media sentiment score.

Company	Overall Sentiment
MorphoSys	Neutral
Gyre Therapeutics	Neutral

Summary

Gyre Therapeutics beats MorphoSys on 12 of the 15 factors compared between the two stocks.

How does Gyre Therapeutics compare to Atai Beckley?

Gyre Therapeutics (NASDAQ:GYRE) and Atai Beckley (NASDAQ:ATAI) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Gyre Therapeutics has a net margin of -15.47% compared to Atai Beckley's net margin of -14,938.36%. Gyre Therapeutics' return on equity of -6.57% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-15.47%	-6.57%	-5.35%
Atai Beckley	-14,938.36%	-88.30%	-58.88%

Gyre Therapeutics presently has a consensus price target of $16.00, indicating a potential upside of 125.04%. Atai Beckley has a consensus price target of $10.56, indicating a potential upside of 43.62%. Given Gyre Therapeutics' higher possible upside, analysts plainly believe Gyre Therapeutics is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06

24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Atai Beckley shares are owned by institutional investors. 9.5% of Gyre Therapeutics shares are owned by insiders. Comparatively, 19.8% of Atai Beckley shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Gyre Therapeutics has a beta of 1.89, suggesting that its share price is 89% more volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market.

In the previous week, Gyre Therapeutics had 2 more articles in the media than Atai Beckley. MarketBeat recorded 2 mentions for Gyre Therapeutics and 0 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.25 beat Gyre Therapeutics' score of 0.00 indicating that Atai Beckley is being referred to more favorably in the news media.

Company	Overall Sentiment
Gyre Therapeutics	Neutral
Atai Beckley	Neutral

Gyre Therapeutics has higher revenue and earnings than Atai Beckley. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	6.80	$5.03M	-$0.21	N/A
Atai Beckley	$4.09M	666.46	-$660.05M	-$2.18	N/A

Summary

Gyre Therapeutics beats Atai Beckley on 10 of the 17 factors compared between the two stocks.

Get Gyre Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GYRE vs. The Competition

Export

Metric	Gyre Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$780.57M	$12.24B	$7.14B	$13.18B
Dividend Yield	N/A	2.64%	2.53%	16.78%
P/E Ratio	-33.86	799.70	275.68	26.04
Price / Sales	6.80	842.54	661.92	103.09
Price / Cash	31.50	82.26	77.60	51.75
Price / Book	4.80	10.46	10.93	6.31
Net Income	$5.03M	$2.84B	$3.51B	$362.16M
7 Day Performance	-3.27%	-1.57%	-2.00%	-1.66%
1 Month Performance	10.40%	-5.67%	-6.15%	-4.50%
1 Year Performance	-4.05%	-4.73%	7.44%	2.06%

Gyre Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GYRE Gyre Therapeutics	1.2762 of 5 stars	$7.11 +1.6%	$16.00 +125.0%	-5.5%	$780.57M	$116.59M	N/A	618	News Coverage Analyst Upgrade Gap Down
ARQT Arcutis Biotherapeutics	3.8227 of 5 stars	$27.78 +7.0%	$35.57 +28.0%	+18.4%	$3.26B	$376.07M	132.29	354	News Coverage
MBX MBX Biosciences	2.8351 of 5 stars	$61.98 +1.7%	$77.00 +24.2%	+249.3%	$2.93B	N/A	N/A	63	Positive News Analyst Forecast
RGC Regencell Bioscience	0.2828 of 5 stars	$6.23 +5.2%	N/A	-57.8%	$2.93B	N/A	N/A	10	News Coverage
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GYRE) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gyre Therapeutics (GYRE) Competitors

GYRE vs. ARQT, MBX, RGC, MOR, and ATAI

How does Gyre Therapeutics compare to Arcutis Biotherapeutics?

Summary

How does Gyre Therapeutics compare to MBX Biosciences?

Summary

How does Gyre Therapeutics compare to Regencell Bioscience?

Summary

How does Gyre Therapeutics compare to MorphoSys?

Summary

How does Gyre Therapeutics compare to Atai Beckley?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GYRE vs. The Competition

Gyre Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gyre Therapeutics (GYRE) Competitors

GYRE vs. ARQT, MBX, RGC, MOR, and ATAI

How does Gyre Therapeutics compare to Arcutis Biotherapeutics?

Which has stronger earnings and valuation, ARQT or GYRE?

Do insiders and institutionals have more ownership in ARQT or GYRE?

Which has more risk and volatility, ARQT or GYRE?

Is ARQT or GYRE more profitable?

Do analysts rate ARQT or GYRE?

Does the media prefer ARQT or GYRE?

Summary

How does Gyre Therapeutics compare to MBX Biosciences?

Which has more risk & volatility, GYRE or MBX?

Is GYRE or MBX more profitable?

Does the media favor GYRE or MBX?

Which has preferable earnings and valuation, GYRE or MBX?

Do insiders & institutionals have more ownership in GYRE or MBX?

Do analysts rate GYRE or MBX?

Summary

How does Gyre Therapeutics compare to Regencell Bioscience?

Do analysts rate RGC or GYRE?

Which has more risk and volatility, RGC or GYRE?

Which has better earnings and valuation, RGC or GYRE?

Is RGC or GYRE more profitable?

Does the media refer more to RGC or GYRE?

Do insiders and institutionals hold more shares of RGC or GYRE?

Summary

How does Gyre Therapeutics compare to MorphoSys?

Do insiders & institutionals have more ownership in MOR or GYRE?

Do analysts prefer MOR or GYRE?

Which has preferable earnings & valuation, MOR or GYRE?

Which has more risk and volatility, MOR or GYRE?

Is MOR or GYRE more profitable?

Does the media prefer MOR or GYRE?

Summary

How does Gyre Therapeutics compare to Atai Beckley?

Is GYRE or ATAI more profitable?

Do analysts prefer GYRE or ATAI?

Do institutionals & insiders believe in GYRE or ATAI?

Which has more risk & volatility, GYRE or ATAI?

Does the media prefer GYRE or ATAI?

Which has better earnings & valuation, GYRE or ATAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GYRE vs. The Competition

Gyre Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools